Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Medarex
Ono Pharma USA Inc
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01024231
First received: December 1, 2009
Last updated: December 6, 2016
Last verified: December 2016